| Literature DB >> 30996509 |
Yusuf Samet Aytekin1, Mustafa Köktürk2, Adam Zaczek3, Timothy M Korter3, Edwin J Heilweil4, Okan Esenturk1.
Abstract
One of the most commonly used nonsteroidal anti-inflammatory active pharmaceutical ingredient called Meloxicam has been characterized spectroscopically both by Terahertz (THz) time domain spectroscopy (THz-TDS) and by Fourier Transform Infrared (FTIR) spectroscopy in far-IR regions of electromagnetic spectrum; 0.2 THz to 20 THz. While many relatively sharp features are observed in the far-IR range between 2 THz to 20 THz as expected for being an organic substance, very distinct and relatively strong absorption bands are also observed at 1.00, 1.66, 2.07 and 2.57 THz in the THz range. These well separated, defined, and fairly strong spectral features can be used for discrimination and quantification of Meloxicam in drug analysis. Frequency dependent refractive index of the drug was determined in a range of 0.2 THz and 2.7 THz, where an almost constant index was observed with an average index of 1.75. Powder XRD, and solid-state Density Functional Theory (SS-DFT) calculations were utilized to determine the crystalline form of the Meloxicam sample in its enolic crystalline form. Single molecule DFT calculations were also performed in all four possible structures of Meloxicam. In addition, the capability of THz waves transmission through common packaging materials is demonstrated for possibility of future on-site analysis. The results suggest that drug analysis will be possible to perform not only at every stage of manufacturing without destruction but also directly at the shelf of a market after development of portable THz technologies.Entities:
Keywords: API characterization; THz-TDS; active pharmaceutical ingredients (API); infrared spectroscopy
Year: 2018 PMID: 30996509 PMCID: PMC6463309 DOI: 10.1016/j.chemphys.2018.04.022
Source DB: PubMed Journal: Chem Phys ISSN: 0301-0104 Impact factor: 2.348